UCB announced 14 posters have been selected for presentation at this year's American Epilepsy Society Meeting, taking place in Baltimore, Maryland, December 6-10. The UCB scientific program includes the presentation of clinical data describing BRIVIACT® (brivaracetam) CV, VIMPAT® (lacosamide) CV, and NAYZILAM® (midazolam) Nasal Spray CIV, now available in the U.S. for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity (i.e., seizure clusters, acute repetitive seizures) that are distinct from a patient's usual seizure pattern in patients with epilepsy 12 years of age and older. Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death. During the meeting, posters on epilepsy research are also scheduled for presentation, as well as UCB's developmental drug candidate, padsevonil. Padsevonil is not yet approved by the FDA. These scientific presentations provide further insight into UCB's epilepsy portfolio and reinforce the company's commitment to generating sustainable patient value for people living with epilepsy around the world. UCB will be presenting five posters on NAYZILAM and hosting a Symposium "Epilepsy Treatment Update for Patients Suffering from Seizure Clusters" tomorrow, December 6, 6:00 - 9:00 PM, at the Baltimore Convention Center, Room 314-315. During the symposium, Patty Shafer RN, MN, Senior Director of Health Information and Resources from the Epilepsy Foundation will discuss the rationale for their Seizure Clusters Workgroup and research. Panelists James Wheless, MD; Patricia Penovich, MD; and David Burdette, MD will discuss misconceptions around seizure clusters, followed by a clinical presentation on NAYZILAM. UCB will also present "Therapeutic Update: The Additional Burden of Generalized Tonic-Clonic Seizures" with lunch on Sunday, December 8, 12:00 - 1:00 PM, at the Hilton, Key Ballroom 8, Second Floor. John Stern, MD will discuss generalized tonic-clonic seizures and the possibility of mitigating their risk through earlier and more effective treatment interventions. About BRIVIACT® (brivaracetam) CV: BRIVIACT® was approved in the U.S. in 2016 as an add-on therapy for adult patients. BRIVIACT was approved as monotherapy for adults in September 2017, and as monotherapy or adjunctive therapy in patients four years of age and older with partial-onset seizures in 2018. BRIVIACT® is available in three formulations: oral tablets, oral solution, and intravenous (IV) injection. About VIMPAT® (lacosamide) CV: VIMPAT® was approved in the U.S. in 2008 as an add-on therapy for adult patients. VIMPAT was approved as monotherapy for adults in August 2014, and as monotherapy or adjunctive therapy in patients four years of age and older with partial-onset seizures in 2017. VIMPAT® is available in three formulations: oral tablets, oral solution, and intravenous (IV) injection. About NAYZILAM® (midazolam) nasal spray CIV: NAYZILAM®, the first and only nasal spray for the acute treatment of seizure clusters in epilepsy patients 12 years and older, was approved by the U.S. FDA in May 2019.